Pulmonary Edema

Pulmonary edema is a pathological condition characterized by the abnormal accumulation of fluid within the extravascular spaces of the lung, specifically within the interstitial tissue and alveolar spaces. This fluid accumulation impairs gas exchange, leading to hypoxemia, respiratory distress, and potentially life-threatening respiratory failure. In veterinary medicine, pulmonary edema is a common clinical entity that can arise from a variety of underlying causes, broadly categorized into cardiogenic (hydrostatic) and non-cardiogenic (permeability) edema. Cardiogenic pulmonary edema results from increased pulmonary capillary hydrostatic pressure, most commonly due to left-sided heart failure, while non-cardiogenic edema results from damage to the alveolar-capillary membrane, leading to increased permeability and protein-rich fluid extravasation. The clinical presentation ranges from mild exercise intolerance to severe respiratory distress with frothy, blood-tinged sputum. Prompt recognition and aggressive management are critical for a favorable outcome.

The etiologies of pulmonary edema in dogs and cats are diverse and can be classified into two main pathophysiological categories: cardiogenic and non-cardiogenic. Cardiogenic pulmonary edema is most frequently caused by left-sided congestive heart failure (CHF) secondary to degenerative mitral valve disease (endocardiosis) in small-breed dogs, dilated cardiomyopathy (DCM) in large-breed dogs, and hypertrophic cardiomyopathy (HCM) in cats. Other cardiac causes include congenital heart defects (e.g., patent ductus arteriosus, ventricular septal defect), arrhythmias, and cardiac neoplasia. Non-cardiogenic pulmonary edema encompasses a wide range of conditions that increase alveolar-capillary permeability, including: (1) Acute respiratory distress syndrome (ARDS) secondary to sepsis, trauma, pancreatitis, or systemic inflammatory response syndrome; (2) Aspiration pneumonia (e.g., inhalation of gastric contents, foreign bodies, or toxic substances); (3) Inhalation of smoke or toxic gases (e.g., carbon monoxide, chlorine); (4) Electrocution (lightning strike or chewing on electrical cords); (5) Near-drowning; (6) Anaphylaxis; (7) Neurogenic pulmonary edema (e.g., head trauma, seizures, or increased intracranial pressure); (8) Drug-induced (e.g., chemotherapeutic agents like doxorubicin, non-steroidal anti-inflammatory drugs in overdose, or opioids); (9) Uremic pneumonitis in advanced renal failure; (10) High-altitude pulmonary edema (rare in veterinary patients). Additionally, pulmonary edema can be caused by lymphatic obstruction (e.g., neoplasia) or decreased plasma oncotic pressure (e.g., hypoalbuminemia from protein-losing nephropathy or enteropathy), though these are less common.

Pulmonary edema is a common clinical syndrome in small animal practice, with the incidence varying based on the underlying etiology. Cardiogenic pulmonary edema is most prevalent in older, small-breed dogs, particularly Cavalier King Charles Spaniels, Dachshunds, and Poodles, due to the high incidence of degenerative mitral valve disease. In cats, cardiogenic pulmonary edema is often associated with hypertrophic cardiomyopathy, which is more common in middle-aged to older male cats, with certain breeds (e.g., Maine Coon, Ragdoll, Persian) having a genetic predisposition. Non-cardiogenic pulmonary edema is less common but can occur in any age, breed, or sex, depending on the inciting cause. For example, aspiration pneumonia is more common in brachycephalic breeds due to upper airway abnormalities, and electrocution is more common in young animals that chew on electrical cords. There is no strong seasonal variation, but certain causes like smoke inhalation may be more common in fire-prone seasons. Overall, pulmonary edema is a significant cause of respiratory distress in emergency settings, and prompt diagnosis is essential.

The pathophysiology of pulmonary edema involves an imbalance in the Starling forces that govern fluid movement across the alveolar-capillary membrane. In cardiogenic pulmonary edema, elevated left atrial pressure (due to left-sided heart failure) is transmitted backward to the pulmonary veins and capillaries, increasing hydrostatic pressure. When this pressure exceeds the plasma oncotic pressure (approximately 25 mmHg), fluid is forced out of the capillaries into the interstitial space. Initially, the lymphatic system can compensate by increasing drainage, but when the rate of fluid filtration exceeds lymphatic capacity, interstitial edema develops. As the condition progresses, fluid floods the alveoli, leading to alveolar edema, surfactant inactivation, and alveolar collapse. This results in ventilation-perfusion mismatch, intrapulmonary shunting, and hypoxemia. In non-cardiogenic pulmonary edema, the primary mechanism is damage to the alveolar-capillary membrane (endothelial and epithelial cells) due to inflammatory mediators (e.g., cytokines, reactive oxygen species, proteases) released during conditions like sepsis, trauma, or aspiration. This damage increases capillary permeability, allowing protein-rich fluid and inflammatory cells to leak into the interstitium and alveoli. The resulting inflammatory cascade can further exacerbate lung injury, leading to ARDS. Neurogenic pulmonary edema is thought to result from a massive sympathetic surge that causes systemic vasoconstriction and transiently increased pulmonary vascular pressure, along with increased capillary permeability. Regardless of the cause, the final common pathway is impaired gas exchange, leading to hypoxemia, hypercapnia, and respiratory acidosis if severe.

Predisposing factors for pulmonary edema vary by etiology. For cardiogenic pulmonary edema, key risk factors include advanced age (typically >7 years in dogs), small breed size, and pre-existing cardiac disease such as mitral valve degeneration or dilated cardiomyopathy. In cats, risk factors include male sex, older age, and breeds with genetic mutations for hypertrophic cardiomyopathy (e.g., Maine Coon, Ragdoll). For non-cardiogenic pulmonary edema, predisposing factors include: (1) Underlying systemic inflammatory conditions (e.g., sepsis, pancreatitis, peritonitis); (2) Trauma, especially head trauma or thoracic trauma; (3) Seizure disorders, particularly generalized tonic-clonic seizures; (4) Upper airway obstruction (e.g., brachycephalic airway syndrome, laryngeal paralysis) leading to negative pressure pulmonary edema; (5) Electrocution, especially in puppies and kittens; (6) Near-drowning; (7) Anaphylactic reactions (e.g., insect stings, vaccines, drugs); (8) Ingestion of toxins (e.g., paraquat, certain snake venoms); (9) Iatrogenic fluid overload during aggressive intravenous fluid therapy; (10) Hypoalbuminemia (e.g., due to protein-losing nephropathy or enteropathy) which reduces plasma oncotic pressure. Additionally, animals with pre-existing respiratory disease (e.g., chronic bronchitis, pneumonia) may be more susceptible to developing pulmonary edema when exposed to additional stressors.

Clinical signs of pulmonary edema can range from subtle to severe and often progress rapidly. In the early stages, animals may exhibit mild tachypnea, increased respiratory effort, and exercise intolerance. As edema worsens, signs become more pronounced and include: (1) Severe respiratory distress with orthopnea (reluctance to lie down, standing with elbows abducted and head extended); (2) Cough, which may be dry initially but becomes productive with frothy, sometimes blood-tinged sputum; (3) Crackles and wheezes on thoracic auscultation, particularly in the caudodorsal lung fields; (4) Cyanosis of mucous membranes in severe cases; (5) Open-mouth breathing in cats; (6) Restlessness, anxiety, and panic due to air hunger; (7) Tachycardia and weak pulses if cardiogenic shock is present; (8) In cardiogenic cases, additional signs of heart failure such as jugular venous distension, hepatomegaly, and ascites may be present; (9) In non-cardiogenic cases, signs of the underlying cause (e.g., fever, vomiting, seizures) may be evident. In peracute cases, animals may present in severe respiratory distress with rapid progression to respiratory failure and collapse. Early recognition of these signs is critical for timely intervention.

Differential diagnoses for pulmonary edema include: (1) Pneumonia (bacterial, viral, fungal, or parasitic): Characterized by fever, productive cough, and pulmonary infiltrates on radiographs that are often cranioventral in distribution; cytology and culture of bronchoalveolar lavage fluid can confirm infectious etiology. (2) Pulmonary thromboembolism (PTE): Presents with acute onset respiratory distress, often with underlying hypercoagulable state (e.g., heartworm disease, hyperadrenocorticism, immune-mediated hemolytic anemia); thoracic radiographs may be normal or show oligemia, and CT angiography is diagnostic. (3) Neoplasia (primary or metastatic): Chronic cough, weight loss, and nodular or interstitial patterns on radiographs; cytology or histopathology is confirmatory. (4) Feline asthma (in cats): Chronic cough, eosinophilic airway inflammation, and bronchial pattern on radiographs; responds to bronchodilators and corticosteroids. (5) Chronic bronchitis (in dogs): Chronic cough, bronchial pattern on radiographs, and airway inflammation on cytology. (6) Pulmonary fibrosis: Progressive exercise intolerance, restrictive pattern on pulmonary function tests, and interstitial pattern on radiographs; definitive diagnosis via histopathology. (7) Pneumothorax: Sudden onset respiratory distress with decreased lung sounds and hyperresonance on thoracic auscultation; radiographs show retracted lung lobes and free air in the pleural space. (8) Pleural effusion: Muffled heart and lung sounds, respiratory distress, and fluid line on thoracic radiographs; thoracocentesis is diagnostic. (9) Upper airway obstruction (e.g., laryngeal paralysis, brachycephalic syndrome): Stridor, inspiratory distress, and normal lung sounds; may lead to negative pressure pulmonary edema. (10) Acute respiratory distress syndrome (ARDS): Severe hypoxemia, bilateral pulmonary infiltrates, and no evidence of cardiogenic edema; often secondary to systemic inflammatory conditions. Differentiating these conditions requires a thorough history, physical examination, thoracic imaging (especially radiography and echocardiography), and advanced diagnostics such as bronchoscopy, CT, and laboratory testing.

The diagnostic approach to a patient with suspected pulmonary edema should be systematic and rapid, especially in emergency settings. Step 1: Triage and stabilization – Assess airway, breathing, and circulation (ABCs). Administer supplemental oxygen, establish intravenous access, and minimize stress. Step 2: History and physical examination – Obtain a thorough history including onset, progression, and any potential triggers (e.g., toxin exposure, trauma, seizures). Perform a complete physical exam with emphasis on respiratory rate and effort, thoracic auscultation, mucous membrane color, and cardiac assessment (murmurs, arrhythmias). Step 3: Thoracic radiography – Obtain orthogonal views (lateral and dorsoventral or ventrodorsal) if the patient is stable. Radiographic findings of pulmonary edema include a diffuse interstitial to alveolar pattern, often with a perihilar distribution in cardiogenic cases, and peripheral distribution in non-cardiogenic cases. Cardiomegaly and pulmonary vessel engorgement may be present in cardiogenic edema. Step 4: Echocardiography – If cardiogenic edema is suspected, perform a focused echocardiogram to assess cardiac structure and function, including left atrial size, ventricular wall thickness, and systolic function. This can help differentiate between mitral valve disease, DCM, and HCM. Step 5: Point-of-care ultrasound (POCUS) – Lung ultrasound can reveal B-lines (comet-tail artifacts) indicative of interstitial edema, and cardiac ultrasound can assess left atrial enlargement. Step 6: Blood work – Perform a complete blood count, serum biochemistry profile, and blood gas analysis. In cardiogenic edema, NT-proBNP levels may be elevated; in non-cardiogenic edema, biomarkers of inflammation (e.g., CRP) may be increased. Step 7: Additional tests – Depending on the suspected cause, consider heartworm antigen testing, urine protein:creatinine ratio, and toxicology screens. Step 8: Advanced imaging – If the diagnosis is unclear, CT angiography may be indicated to rule out pulmonary thromboembolism or other structural lesions. Step 9: Bronchoalveolar lavage – If infectious or inflammatory causes are suspected, perform bronchoscopy with BAL for cytology and culture. Step 10: Response to therapy – Monitor response to diuretics and oxygen; improvement supports cardiogenic edema, while lack of response may indicate non-cardiogenic causes. This algorithm ensures a comprehensive evaluation while prioritizing patient stability.

Laboratory findings in pulmonary edema are non-specific but can support the diagnosis and identify underlying causes. Hematology: In cardiogenic edema, the CBC is often unremarkable, but stress leukogram (neutrophilia, lymphopenia, eosinopenia) may be present. In non-cardiogenic edema due to inflammation or infection, leukocytosis with a left shift may be seen. Serum biochemistry: In cardiogenic edema, renal values may be mildly elevated due to decreased cardiac output and prerenal azotemia. Liver enzymes may be elevated due to hepatic congestion. In non-cardiogenic edema, elevations in amylase and lipase may indicate pancreatitis, and hypoalbuminemia may be present in protein-losing conditions. Blood gas analysis: Arterial blood gas typically reveals hypoxemia (decreased PaO2) and, in severe cases, hypercapnia and respiratory acidosis. The alveolar-arterial oxygen gradient is increased. Urinalysis: May show proteinuria in cases of protein-losing nephropathy. Specific biomarkers: NT-proBNP is a useful point-of-care test for differentiating cardiogenic from non-cardiogenic pulmonary edema; elevated levels (>900 pmol/L in dogs, >100 pmol/L in cats) support cardiac disease. Cardiac troponin I may be elevated in myocardial injury. Inflammatory markers such as C-reactive protein (CRP) may be increased in non-cardiogenic edema. Serology/PCR: Depending on suspected infectious causes (e.g., heartworm, fungal, bacterial), appropriate tests should be performed. Endocrine assays: If hyperadrenocorticism is suspected as a cause of hypertension and edema, ACTH stimulation test or low-dose dexamethasone suppression test may be indicated. Overall, laboratory findings are most useful for identifying underlying systemic diseases and assessing organ function.

Imaging plays a crucial role in the diagnosis and management of pulmonary edema. Thoracic radiography is the primary imaging modality. In cardiogenic pulmonary edema, typical findings include: (1) Cardiomegaly (enlarged cardiac silhouette, especially left atrial and left ventricular enlargement); (2) Pulmonary venous distension; (3) Interstitial to alveolar pattern, often with a perihilar (butterfly) distribution in dogs, while cats may show a more patchy or diffuse distribution; (4) Air bronchograms in severe alveolar edema. In non-cardiogenic pulmonary edema, the distribution is often more peripheral and patchy, and the heart size is usually normal. Thoracic radiography is also useful for monitoring response to therapy. Echocardiography is essential for diagnosing underlying cardiac disease. It can assess chamber dimensions, wall thickness, systolic function (ejection fraction), and valvular morphology. In dogs with mitral valve disease, echocardiography shows thickened mitral valve leaflets and left atrial enlargement. In cats with HCM, there is concentric left ventricular hypertrophy. Point-of-care ultrasound (POCUS) of the lungs can rapidly detect B-lines, which are vertical artifacts indicating interstitial edema. This is particularly useful in emergency settings. Computed tomography (CT) is more sensitive than radiography for detecting early pulmonary edema and can help differentiate it from other conditions such as pulmonary thromboembolism or neoplasia. CT angiography is the gold standard for diagnosing PTE. Magnetic resonance imaging (MRI) is rarely used for pulmonary edema but may be helpful in research settings. Fluoroscopy can be used to assess dynamic airway collapse, which may be a predisposing factor. Overall, imaging findings must be interpreted in conjunction with clinical signs and laboratory data.

Cytology and histopathology are not routinely required for the diagnosis of pulmonary edema, but they can be helpful in certain situations. Bronchoalveolar lavage (BAL) fluid cytology may be performed to rule out infectious or inflammatory causes. In cardiogenic pulmonary edema, BAL fluid is typically a transudate with low protein content and few cells. In non-cardiogenic edema, BAL fluid may be more proteinaceous and contain inflammatory cells (neutrophils, macrophages) depending on the underlying cause. Histopathology of lung tissue is rarely performed antemortem but may be obtained postmortem. Grossly, the lungs are heavy, wet, and fail to collapse. Microscopically, there is alveolar edema fluid, which may be proteinaceous in permeability edema, and there may be evidence of underlying disease such as cardiac changes or inflammation. Special stains (e.g., Prussian blue for hemosiderin) can help identify chronic hemorrhage. In cases of suspected ARDS, histopathology may show hyaline membranes, alveolar hemorrhage, and interstitial inflammation. However, in clinical practice, the diagnosis of pulmonary edema is usually made based on imaging and response to therapy, and invasive sampling is reserved for cases where the cause is unclear or when infection is suspected.

Treatment of pulmonary edema is aimed at improving oxygenation, reducing fluid accumulation, and addressing the underlying cause. Emergency stabilization is the first priority: (1) Oxygen supplementation: Administer 100% oxygen via flow-by, mask, or oxygen cage. In severe cases, mechanical ventilation may be necessary. (2) Diuretics: Furosemide is the mainstay of therapy for cardiogenic pulmonary edema. Administer at a dose of 2-4 mg/kg IV or IM initially, then 1-2 mg/kg every 1-8 hours as needed. In non-cardiogenic edema, diuretics may be used cautiously but are less effective. (3) Vasodilators: In cardiogenic edema, nitroprusside (0.5-10 µg/kg/min IV CRI) or hydralazine (0.5-2 mg/kg PO q12h) can reduce afterload and preload. (4) Positive inotropes: In cases of systolic dysfunction (e.g., DCM), pimobendan (0.3 mg/kg PO q12h) or dobutamine (5-20 µg/kg/min IV CRI) may be used. (5) Bronchodilators: Aminophylline (5-10 mg/kg IV or PO q8h) or terbutaline (0.01 mg/kg SC or 0.625-1.25 mg/cat PO q12h) can help relieve bronchospasm. (6) Corticosteroids: In non-cardiogenic edema due to inflammatory causes, dexamethasone (0.1-0.2 mg/kg IV) or prednisone (0.5-1 mg/kg PO q12h) may be used, but their efficacy is controversial. (7) Antibiotics: If infection is suspected, broad-spectrum antibiotics such as amoxicillin-clavulanate (12.5-25 mg/kg PO q12h) or enrofloxacin (5-10 mg/kg PO or IV q24h) should be initiated. (8) Supportive care: Maintain adequate hydration, but avoid fluid overload. Use colloids (e.g., hetastarch) if hypoalbuminemia is present. (9) Treat underlying cause: For example, antiarrhythmics for arrhythmias, anticonvulsants for seizures, or surgical correction of congenital defects. (10) Mechanical ventilation: Indicated for severe hypoxemia (PaO2 <60 mmHg) or hypercapnia despite oxygen therapy. The prognosis depends on the underlying cause and the speed of intervention.

The prognosis for pulmonary edema varies widely depending on the underlying cause and the severity of respiratory compromise. For cardiogenic pulmonary edema, the short-term prognosis is good if treated aggressively with diuretics and oxygen; however, the long-term prognosis is guarded due to the progressive nature of heart disease. Median survival times for dogs with congestive heart failure secondary to mitral valve disease are approximately 9-12 months with appropriate therapy. For cats with HCM and pulmonary edema, survival times are variable, with some cats living for years with good management. Non-cardiogenic pulmonary edema has a more guarded prognosis, especially if associated with ARDS or severe systemic disease. Mortality rates for ARDS in veterinary patients are high (50-70%). However, if the underlying cause is reversible (e.g., electrocution, near-drowning), the prognosis can be good with prompt supportive care. Negative prognostic indicators include: (1) Severe hypoxemia (PaO2/FiO2 ratio <200); (2) Need for mechanical ventilation; (3) Presence of multiple organ dysfunction; (4) Lack of response to initial therapy; (5) Advanced age and concurrent diseases. Early recognition and aggressive management are key to improving outcomes.

Follow-up care for patients with pulmonary edema is essential to monitor response to therapy and adjust medications. Initially, patients should be re-evaluated every 1-2 days until respiratory signs stabilize. Serial thoracic radiographs should be performed to assess resolution of edema; radiographs may lag behind clinical improvement by 12-24 hours. Blood work, including renal values and electrolytes, should be monitored regularly, especially in patients on diuretics. For cardiogenic edema, long-term management includes: (1) Furosemide at the lowest effective dose (typically 1-2 mg/kg PO q12h, adjusted based on body weight and clinical signs); (2) Pimobendan (0.3 mg/kg PO q12h) for dogs with DCM or mitral valve disease; (3) ACE inhibitors such as enalapril (0.5 mg/kg PO q12h) or benazepril (0.25-0.5 mg/kg PO q12h); (4) Spironolactone (1-2 mg/kg PO q12h) as an adjunct diuretic; (5) Dietary sodium restriction. Recheck examinations should be scheduled every 1-3 months, with echocardiography every 6-12 months to assess disease progression. For non-cardiogenic edema, follow-up depends on the underlying cause. If the cause was aspiration pneumonia, repeat radiographs and clinical assessment are needed until resolution. If the cause was toxin exposure, monitor for long-term organ damage. Owners should be educated on signs of recurrence (e.g., increased respiratory rate, coughing, lethargy) and advised to seek immediate veterinary care if these occur. Overall, a structured follow-up plan is crucial for optimizing long-term outcomes.

Pearls: (1) In any dyspneic patient, minimize stress and handling; allow the animal to remain in a comfortable position (sternal or sitting) and provide oxygen immediately. (2) Thoracic radiography should be performed as soon as the patient is stable, but avoid forcing the animal into dorsal recumbency if it is in severe respiratory distress. (3) In cats, avoid using acepromazine for sedation as it can cause hypotension and worsen edema; butorphanol (0.2-0.4 mg/kg IV) is a safer choice. (4) Furosemide is the most effective drug for cardiogenic pulmonary edema; administer IV for rapid onset. (5) In non-cardiogenic edema, furosemide may not be as effective and can cause dehydration; use it cautiously. (6) Point-of-care lung ultrasound is a rapid and sensitive tool for detecting pulmonary edema; B-lines are highly suggestive. (7) NT-proBNP is a valuable biomarker to differentiate cardiogenic from non-cardiogenic edema; a negative result makes cardiogenic edema unlikely. (8) Always check for underlying causes such as heartworm disease, especially in endemic areas. Pitfalls: (1) Do not delay diuretic therapy in a patient with suspected cardiogenic edema while waiting for radiographs; if the patient is unstable, treat empirically. (2) Avoid over-diuresis, which can lead to prerenal azotemia and electrolyte imbalances; monitor renal values and body weight. (3) Do not use corticosteroids in cases of aspiration pneumonia, as they can worsen infection. (4) Do not administer fluids aggressively in patients with pulmonary edema; use minimal fluid rates (e.g., 2-3 ml/kg/hr) and consider colloids if needed. (5) Do not overlook the possibility of upper airway obstruction causing negative pressure pulmonary edema; address the obstruction promptly. (6) In cats, avoid using oxygen masks that cause stress; use an oxygen cage instead. (7) Do not assume all pulmonary edema is cardiogenic; always consider non-cardiogenic causes, especially in young animals with no history of heart disease.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for pulmonary edema: (1) Furosemide: Dogs and cats: 2-4 mg/kg IV, IM, or SC initially; may repeat at 1-2 mg/kg every 1-2 hours until respiratory distress improves, then taper to 1-2 mg/kg PO q8-12h. For severe cases, a continuous rate infusion (CRI) of 0.66-1 mg/kg/hr IV may be used. (2) Nitroprusside: Dogs: 0.5-10 µg/kg/min IV CRI, titrated to effect; cats: 0.5-2 µg/kg/min IV CRI. Use with caution in patients with renal or hepatic impairment. (3) Hydralazine: Dogs: 0.5-2 mg/kg PO q12h; cats: 2.5 mg/cat PO q12h. (4) Pimobendan: Dogs: 0.3 mg/kg PO q12h; cats: 1.25 mg/cat PO q12h (off-label). (5) Dobutamine: Dogs: 5-20 µg/kg/min IV CRI; cats: 1-5 µg/kg/min IV CRI. (6) Aminophylline: Dogs: 5-10 mg/kg IV, IM, or PO q8h; cats: 5 mg/kg IV or PO q12h. (7) Terbutaline: Dogs: 0.01 mg/kg SC or 0.625-1.25 mg/dog PO q8-12h; cats: 0.625-1.25 mg/cat PO q12h. (8) Dexamethasone: Dogs and cats: 0.1-0.2 mg/kg IV q12-24h for non-cardiogenic edema. (9) Prednisone: Dogs: 0.5-1 mg/kg PO q12h; cats: 1-2 mg/kg PO q12h. (10) Antibiotics: Amoxicillin-clavulanate: Dogs and cats: 12.5-25 mg/kg PO q12h; Enrofloxacin: Dogs: 5-10 mg/kg PO or IV q24h; Cats: 5 mg/kg PO or IV q24h. (11) Enalapril: Dogs: 0.5 mg/kg PO q12h; Cats: 0.25-0.5 mg/kg PO q12h. (12) Spironolactone: Dogs: 1-2 mg/kg PO q12h; Cats: 1-2 mg/kg PO q12h. (13) Butorphanol: Dogs: 0.2-0.4 mg/kg IV; Cats: 0.2-0.4 mg/kg IV. (14) Oxygen: 100% via mask, flow-by, or oxygen cage; mechanical ventilation if needed. Dosages should be adjusted based on renal/hepatic function, and drug interactions should be considered (e.g., furosemide with aminoglycosides increases ototoxicity).

Evidence-based literature on pulmonary edema in veterinary medicine is extensive. Key studies include: (1) The EPIC study (Evaluation of Pimobendan in dogs with Cardiomegaly caused by preclinical myxomatous mitral valve disease) demonstrated that pimobendan delays the onset of congestive heart failure in dogs with preclinical mitral valve disease. (2) The QUEST study (Quality of life and Extension of Survival time) showed that pimobendan significantly prolongs survival in dogs with congestive heart failure due to myxomatous mitral valve disease compared to benazepril. (3) ACVIM consensus statements on the diagnosis and treatment of myxomatous mitral valve disease (2019) and on the diagnosis and management of feline hypertrophic cardiomyopathy (2020) provide evidence-based guidelines. (4) Studies on the use of NT-proBNP have shown high sensitivity and specificity for differentiating cardiogenic from non-cardiogenic respiratory distress. (5) Research on ARDS in veterinary patients has established diagnostic criteria (e.g., the Veterinary Acute Lung Injury and ARDS (VALI) criteria) and highlighted the high mortality rate. (6) Studies on lung ultrasound have demonstrated its utility in detecting pulmonary edema in dogs and cats. (7) Clinical trials on furosemide have established its efficacy and dosing protocols in heart failure. (8) Research on aspiration pneumonia has identified risk factors and optimal antibiotic therapy. Overall, the evidence supports a multimodal approach to treatment, with a focus on addressing the underlying cause and providing aggressive supportive care.